Form 4: GeneDx CEO Sell-to-Cover Trade and RSU Settlement Details
Rhea-AI Filing Summary
Insider transactions reported for GeneDx Holdings Corp. (WGS) show Katherine Stueland received 18,750 restricted stock units (RSUs) on 09/16/2025 that convert to Class A common stock for no cash consideration upon settlement, and sold 10,501 shares of Class A common stock the same day at a weighted-average price of $121.4727 per share as part of a block trade. The sale was disclosed as a "sell to cover" transaction to satisfy tax withholding tied to the RSU vesting and was not discretionary. After these transactions the reporting person directly beneficially owned 14,578 shares of Class A common stock and, separately, beneficially owned RSUs representing up to 444,539 shares and options for 107,610 shares, subject to their vesting terms.
Positive
- None.
Negative
- None.
Insights
TL;DR: Routine "sell to cover" tax-sale tied to RSU settlement; insider still holds significant equity exposure via RSUs and options.
The Form 4 reports a non-discretionary sale of 10,501 shares at a weighted-average price of $121.4727 to satisfy withholding obligations arising from the vesting/settlement of 18,750 RSUs. Such tax-driven sales are common and do not necessarily signal a change in management conviction. Material ongoing equity exposure remains: the reporting person beneficially owns 14,578 shares plus RSUs convertible to up to 444,539 shares and options for 107,610 shares, subject to vesting schedules. The disclosure is detailed and includes an undertaking to provide per-price breakdowns for the block trade.
TL;DR: Transaction is administrative (tax withholding) and governance disclosure is complete; significant unvested equity aligns executive incentives with shareholders.
The filing documents receipt of 18,750 RSUs exercisable for Class A shares at $0 consideration and a contemporaneous sale to cover taxes. The form identifies the reporting person as both a director and the Chief Executive Officer, which underscores the governance importance of clearly reporting such transactions. The disclosure of aggregate unvested RSUs (444,539) and options (107,610) provides transparency on potential future dilution and executive alignment. No discretionary insider selling is reported.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Unit | 18,750 | $0.00 | -- |
| Exercise | Class A Common Stock | 18,750 | $0.00 | -- |
| Sale | Class A Common Stock | 10,501 | $121.4727 | $1.28M |
Footnotes (1)
- Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The price reported is a weighted average price. These shares were sold as part of a block trade for multiple security holders of the Issuer in multiple transactions at prices ranging from $118.28 to $123.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 with regard to the block trade. Following the reported sales, in addition to the 14,578 shares of Class A common stock beneficially owned by the Reporting Person, the Reporting Person beneficially owned restricted stock units ("RSUs") representing contingent rights to receive up to an aggregate of 444,539 shares of Class A common stock and options to purchase up to an aggregate of 107,610 shares of Class A common stock, which RSUs and options vest according to their respective terms. 6.25% vest in quarterly installments over the 4-year period commencing on March 16, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
